Selective TRβ Agonist Compounds for NAFLD Without Cardiotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Endogenous thyroid hormones are non-selective and cause side effects such as hyperthyroidism, particularly cardiovascular toxicity, limiting their therapeutic benefits for conditions like obesity, hyperlipidemia, diabetes, and non-alcoholic fatty liver disease.
Innovation Solution
Development of thyroid hormone β receptor agonists with specific compounds that selectively activate thyroid hormone β receptors, minimizing side effects while maintaining therapeutic benefits.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If thyroid hormone is used to treat metabolic disorders and obesity, then metabolic rate increases and body weight reduces, but cardiovascular toxicity and hyperthyroidism side effects occur
Solution Approach 1:
The patent applies local quality by developing selective TRβ1 agonists that target specific tissue receptors (thyroid hormone beta receptor 1) rather than acting on all thyroid hormone receptors. This selectivity allows the drug to produce metabolic benefits in the liver and adipose tissue while avoiding the cardiovascular side effects associated with non-selective thyroid hormone activation.
Solution Approach 2:
The patent uses selective thyroid hormone analogs as intermediaries that mimic the beneficial effects of natural thyroid hormone through TRβ1 receptor activation, while the molecular structure of these analogs is designed to minimize activation of other receptor subtypes that cause cardiovascular toxicity.
2Productivity
If non-selective thyroid hormone analogs are used to treat obesity and metabolic disorders, then weight loss is achieved, but adverse effects such as hyperthyroidism occur
Solution Approach 1:
The patent employs local quality by creating highly selective TRβ1 receptor agonists that act specifically on the thyroid hormone beta receptor 1 subtype. This selectivity ensures that weight loss benefits are achieved through targeted metabolic regulation in adipose tissue and liver, while avoiding the systemic hyperthyroidism caused by non-selective analogs.
Solution Approach 2:
The patent applies parameter changes by modifying the molecular structure of thyroid hormone analogs to change their receptor binding specificity. The chemical structures are designed to have high affinity for TRβ1 while having minimal affinity for other thyroid hormone receptor subtypes, thereby changing the pharmacological parameters to achieve selectivity.
3Reliability
If existing thyroid hormone therapies are used for atherosclerosis and hypercholesterolemia, then lipid metabolism is improved, but cardiovascular toxicity increases
Solution Approach 1:
The patent applies local quality by targeting TRβ1 receptors specifically in the liver, where they play a key role in cholesterol metabolism and LDL receptor regulation. This localized action improves lipid metabolism without the cardiovascular toxicity associated with systemic thyroid hormone activation.
Solution Approach 2:
The patent uses selective TRβ1 agonists as intermediary substances that mediate the beneficial effects on lipid metabolism through specific receptor activation, avoiding the harmful cardiovascular effects of non-selective thyroid hormone therapy.
Data Source
AI summary
Provided is a chemical compound as a thyroid hormone Beta receptor agonist and a use thereof, further comprising a pharmaceutical composition containing the chemical compound. The chemical compound or pharmaceutical composition can be used in the preparation of drugs for preventing, treating or mitigation of diseases mediated by agonistic thyroid hormone β receptor, particularly for the preparation of drugs for treating non-alcoholic fatty liver diseases.